Published: 2019 April 09

Diabetic Macular Edema Market Size, Competitive Landscape and Market Forecast - 2029

SKU : PH30
180 pages
Report Summary
Table of Contents

Global Diabetic Macular Edema Market Is Segmented By Therapy Type (Anti-VEGF, Corticosteroids, Other Off-label Drugs), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

The Global Diabetic Macular Edema Market is expected to grow at a CAGR of 1.1% during the forecasting period (2022-2029).

  • Diabetic Macular Edema (DME) is the accumulation of fluid in the macula part of the retina due to leaking blood vessels.
  • DME is a major complication of diabetes and a leading cause of vision loss in persons with diabetes mellitus.
  • The Global Diabetic Macular Edema market is estimated to grow to USD 4.1 billion by 2027.

Market Dynamics

  • Increasing the prevalence of diabetes is the prime factor driving the growth of the Diabetic Macular Edema market.
  • Globally, an estimated 422 million adults are living with diabetes.
  • Besides, substantial R&D investment by pharmaceutical companies and the launch of several promising emerging therapies will fuel market growth.
  • However, unfavorable reimbursement policies will restrict market growth.

Market Segmentation

  • Global Diabetic Macular Edema market report segments the market by therapy type, product type, distribution channel, and region.
  • Based on the therapy type, the diabetic macular edema market has been classified into anti-VEGF, corticosteroids, and other off-label drugs.
  • Although laser photocoagulation therapy is being used as standard DME treatment for 25 years, the approval of anti-VEGF has revolutionized the treatment of DME.
  • Based on the distribution channel, the market has been segmented into Hospital Pharmacy, Retail Pharmacy, and Others.
  • Regionally, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
  • North America will dominate the market owing to the high prevalence of diabetes, high awareness among people about DME, availability of treatment options, and better reimbursement policies in the region.
  • In 2017, North America accounted for around 51% revenue share of the global market.

Market Competitive Analysis

  • The report also profiles the following companies of the Diabetic Macular Edema market – Novartis, Roche, Allergan, Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., Pfizer Inc., Bayer AG, and Bausch & Lomb Incorporated.

By Therapy Type

  • Anti-VEGF
  • Corticosteroids
  • Other Off-label Drugs

By Product Type

  • Intravitreal Injections
  • Intravitreal Implants

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

By Region

  • Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
  • Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
  • North America (The USA, Canada, Mexico)
  • South America (Brazil, Argentina, Rest of South America)
  • Rest of the World

Trending Topics

Macular Edema Market

Diabetic Foot Ulcer Market

Remote Patient Monitoring Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy